



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/073,135	02/13/2002	Akemichi Baba	010541A	5435
23850	7590	02/13/2004	EXAMINER	
ARMSTRONG, KRATZ, QUINTOS, HANSON & BROOKS, LLP 1725 K STREET, NW SUITE 1000 WASHINGTON, DC 20006			QIAN, CELINE X	
			ART UNIT	PAPER NUMBER
			1636	

DATE MAILED: 02/13/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/073,135

Applicant(s)

BABA ET AL.

Examiner

Celine X Qian

Art Unit

1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-8 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-8 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 13 February 2002 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☒ None of:
1. ☒ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>2/13/02</u> . | 6) <input checked="" type="checkbox"/> Other: <u>notice to comply</u> |

Art Unit: 1636

DETAILED ACTION

Claims 1-8 are pending in the application.

Priority

Acknowledgment is made of applicant's claim for foreign priority based on an application filed in Japan on 4/19/00. It is noted, however, that applicant has not filed a certified copy of the 2000-118088 application as required by 35 U.S.C. 119(b).

Sequence Compliance

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Sequences are disclosed in the specification and/or figures that are not identified by their sequence identifier (i.e., SEQ ID NO:). On page 17, several nucleic acid sequences are disclosed, but none are identified by their sequence identifier. **Applicant is reminded that the entire specification and figures should be reviewed for sequence disclosures** and that each sequence disclosed in the specification must be identified by its sequence identifier (i.e., SEQ ID NO:). The specification must be amended to identify all disclosed sequences by their sequence identifier (i.e., SEQ ID NO), in accordance with 37 CFR 1.821(d).

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Art Unit: 1636

Claims 1-6 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. It is PTO policy not to issue claims that encompass humans (see 1077 OG 24, April 21, 1987). This rejection may be overcome by inserting "non-human" before "mammalian".

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-8 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is "undue." These factors include, but are not limited to: (a) the nature of the invention; (b) the breadth of the claims; (c) the state of the prior art; (d) the amount of direction provided by the inventor; (e) the existence of working examples; (f) the relative skill of those in the art; (g) whether the quantity of experimentation needed to make or use the invention based on the content of the disclosure is "undue"; and (h) the level of predictability in the art (MPEP 2164.01 (a)).

Nature of the Invention:

Art Unit: 1636

Claims 1-8 are drawn to a mammalian model animal for psychiatric disorders having a chromosome of a somatic cell and a germ cell with deficiency of function of pituitary adenylate cyclase activating polypeptide (PACAP) gene. Thus, the nature of the invention is directed to transgenic animals for use as a disease model.

Breadth of Claims:

In the instant case, the claims 1-8 encompass any transgenic mammal comprising any deficiency of function of the endogenous PACAP gene regardless of the phenotype.

The specification does not provide an enabling disclosure for the claimed transgenic mammal. The phenotype of the mammalian model animal is critical or essential to the practice of the invention, but not included in the claim(s). Thus the breadth of claims is very broad and encompasses any transgenic mammal and a transgenic mouse having any type of deficient function of the endogenous PACAP gene in both a somatic and germ cell regardless of its phenotype.

Amount of guidance in the specification and Working Examples:

The specification discloses the use of a PACAP knockout mouse and using the homozygous knockout mouse to as a model for psychiatric disorder that displays symptoms same as the knockout mouse. The specification teaches that the knockout mouse exhibits phenotypic changes that include hyperactivity in a novel environment, increased exploration, reduced anxiety, which is reversible by haloperidol, and decreased 5-HIAA level in cortex and striatum, as compared to wild type mice.

The specification provides a working example to make a homozygous, knockout mouse containing two disrupted alleles at exon 5 for the gene that encodes a murine PACAP, wherein

Art Unit: 1636

said disruption results in complete loss of expression of the PACAP. The specification does not teach how to make and use the invention with other species of transgenic or knockout mammals and with any knockout mouse with any form deficiency of function of the PACAP gene, as claimed in the claims 1-8. Further, the specification does not teach how to use the transgenic mammals that without the disclosed phenotype. Therefore, the claimed invention is not enabled by the disclosure because the critical elements for use the invention is not included in the claim. (See *In re Mayhew*, 527 F.2d 1229, 188 USPQ 356 (CCPA 1976)). Moreover, the specification does not teach what type of psychiatric disorder is related to the phenotype that is exhibited by the PACAP knockout mouse. The specification also fails to teach how to use this knockout mouse for any type of psychiatric disorder. As such, the nexus between the exhibited phenotype of the PACAP knockout mouse and psychiatric disorder is missing.

State of the Art, Predictability or Unpredictability of the art, Amount of experimentation necessary and Skill level of the artisan:

Although the skill of an artisan in this subject area is considered to be very high, it would require undue experimentation on the part of an artisan to make and use the claims as specified and use the invention with the transgenic animals as claimed. The specification provides a working example for making only a homozygous, knockout mouse containing two disrupted alleles for the gene that encodes the PACAP, wherein the gene knocked out results in a no expression of the PACAP. However, neither the specification nor the working examples provide enough guidance on how to practice the invention with any other transgenic animals and/or transgenic mice carrying any other type of mutation of the transgene(s) that result in deficiency

Art Unit: 1636

of function of the PACAP. In addition, the specification fails to teach how to use the PACAP knockout mouse as a psychiatric model.

When considering the predictability of this invention, one has to remember that many of the phenotypes examined in transgenic and knockout models are influenced by the genetic background in which they are studied and the effect of allelic variation and the interaction between the allelic variants (pg.1425, paragraph 1 in Sigmund, C.D. 2000. *Arterioscler Thromb Vasc Biol.*20:1425-1429). The claims encompass heterozygotes, but since heterozygotes have one functional allele, the heterozygotes would not be expected to have the same phenotype as the homozygotes. Thus, the phenotype of a heterozygous transgenic or knockout animal is unpredictable. The specification discloses the phenotype of a homozygous PACAP gene knockout mouse comprising a disruption in the exon 5 of the PACAP gene, but fails to disclose the phenotypes of any other knockout mammals with a deficiency of function of the PACAP gene. Thus, the phenotype of any other PACAP transgenic or knockout mammal is unpredictable. Thus, the specification, in the instant case, is not enabling for transgenic and/or knock out mammals, including mice, that exhibit no phenotype or that exhibit transgene-dependent phenotypes other than that disclosed in the instant specification.

Further, the transgene expression and the physiological consequences of transgene products are not always accurately predicted in transgenic mouse studies (pg.62, paragraph1, lines 7-9 in Wall, R.J. 1996. *Theriogenology* 45:57-68). Thus, the invention while being enabled for a homozygous knockout mouse containing two disrupted alleles for the PACAP gene, does not extend the predictability to any other animal systems.

The particular genetic elements required for expression varies from species to species. Our lack of understanding of essential genetic control elements makes it difficult to design transgenes with predictable behavior (Wall, 1996). Therefore, the phenotype of knockout animals is not always predictable. For example, Jacks et al. (1992) describe Rb KO mice that do not display retinoblastoma; rather they exhibit the unexpected phenotype of pituitary tumors. The pituitary tumors arise from cells lacking a wild-type Rb allele. Thus, tumors were found to arise not in retinas, as in humans, but in the pituitary gland (page 299, Discussion, paragraphs 1 and 3). Therefore, in the absence of specific guidance and working examples, the production of transgenic animals with the scope as claimed is unpredictable. In such a situation, one skilled in the art would not know how to make and use the invention as claimed, without undue experimentation.

The specification fails to provide an enabling disclosure for the preparation of other species of knockout mammals besides mice having a disruption in the PACAP gene because the guidance offered in the specification is limited to the preparation of mice harboring such mutations, and no teachings or guidance are offered in regard to how one would have prepared any other type of animal having the recited gene disruption. Since homologous recombination is required for gene targeting methods such as employed in the instant invention, embryonic stem (ES) cell technology must be available to carry out the method. The only species in which such technology was known was the mouse and the artisan did not accept that it was possible to have prepared ES cells in other species (see e.g. Bradley et al., paragraph bridging pages 537-538). Campbell and Wilmut, 1997 acknowledge reports of ES-like cell lines in a number of species, but emphasize that yet there are no reports of any cell lines which contribute to the germ line in

Art Unit: 1636

any species other than the mouse (p. 65). Likewise, Mullins et al. (1996) teach that "[a]lthough to date chimeric animals have been generated from several species including the pig, in no species other than the mouse has germline transmission of an ES cell been successfully demonstrated. This remains a major goal for the future and may well require the use of novel strategies which depart widely from the traditional methods used in the mouse" (p. S38, column 1, paragraph 1. Thus, knockout animals cannot be prepared for any species other than the mouse.

The specification describes two alternative methods for inserting an external gene into an animal or its progeny by either inserting a genomic DNA into a pronuclear embryonic phase of a fertilized ovum or infecting the early phase embryo of the animal with the recombinant retrovirus using a genomic DNA followed by implanting the embryo into a host animal. Although these two methods are known in the art for delivering external genes into host animals other than mouse, both of these methods can only result in random incorporation of external gene to the host genome; therefore targeted insertion of the heterologous DNA sequence specifically into exon 5 of the PACAP coding region is completely unpredictable. Thus, the phenotype of the transgenic mammal made by such methods is also unpredictable. Since ES cell technology is required to produce the claimed animals, in the absence of such technology available in other species, one skilled in the art would have been required to exercise undue experimentation to produce the claimed animals and to practice of the claimed methods in species other than mice.

In view of the limited guidance in the specification, and limited working examples directed to transgenic, knockout mice with a specific knockout gene and exhibiting a specific phenotype, and the unpredictability of the art, one skilled in the art would be required to engage

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: The specification and/or figures must be amended to identify all disclosed sequences by their sequence identifier (i.e., SEQ ID NO), in accordance with 37 CFR 1.821(d). Since the specification and/or figures disclose sequences that are not identified by their sequence identifiers, it is unclear if all disclosed sequences are included in the sequence listing. A substitute CRF and paper copy of the Sequence Listing are required **only** if the unidentified sequences are not already included in the Sequence Listing.

Applicant Must Provide:

- ☐ An **substitute** computer readable form (CRF) copy of the "Sequence Listing".
- ☐ A **substitute** paper copy of the "Sequence Listing", as well as an **amendment directing its entry into the specification**.
- ☐ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Art Unit: 1636

in undue experimentation, in order to make and use the invention as claimed. Thus, the invention is not enabled.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celine X Qian whose telephone number is 571-272-0777. The examiner can normally be reached on 9:30-6:00 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel Ph.D. can be reached on 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Celine Qian, Ph.D.

Anne-Marie Falk
ANNE-MARIE FALK, PH.D
PRIMARY EXAMINER